Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope (Q80150785)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Shan Lu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Susan Zolla-Pazner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sandra Sharpe Cohen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Shixia Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Abraham Pinter

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

3 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

233-246

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Influence of membrane fluidity on human immunodeficiency virus type 1 entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Resting cell neutralization assay for HIV-1 primary isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Identification of HIV vaccine candidate peptides by screening random phage epitope libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Combination DNA plus protein HIV vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

HIV-1 antibody--debris or virion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

A cytopathic infectivity assay of human immunodeficiency virus type 1 in human primary macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Identifying epitopes of HIV-1 that induce protective antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

7 January 2021

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

7 January 2021

Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

7 January 2021

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2007.09.024

7 January 2021

10.1016/J.VIROL.2007.09.024

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18061228%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference